AI Designs Reprogramming Drugs, Boosting Efficiency 3x
jacobkimmel · x · 2026-07-11
This update discusses how advanced AI systems are being used for the virtual design of "cellular reprogramming drugs" prior to physical lab experiments.
The core breakthrough: models previously trained on only a single cell type or lineage achieved cross-lineage generalization this summer. Consequently, data learned from one project can directly benefit others, resulting in a >3x improvement in sample efficiency and reducing the number of real experiments needed to launch new projects.
They also shared two experimental updates:
- In a newly launched vascular endothelial repair project, the team quickly set up an assay for age-related functional damage and identified 5 payloads that make older endothelial cells genetically resemble younger cells while improving regenerative function.
- In a metabolic recovery project, candidate drugs accelerated recovery after alcohol consumption in aged animal models, with this enhanced resilience persisting beyond the initial dosage.
More from Companies & People
- Mystery app icon spotted on Apple exec's unreleased foldable iPhone sparks guessing — demian_ai · 2026-10-26
- Shopify design lead on AI-era workflow: designers are becoming full-stack editors — KlausCodes · 2026-10-26
- Anthropic mocked for warning of existential AI risk while pouring $750B into accelerating it — R4nsack · 2026-10-26
- AI Dev NYC lands Nov 30–Dec 1 with Andrew Ng, Yann LeCun fireside chat on world models — DeepLearningAI · 2026-10-26
- Google expands paid News AI pilot to 400+ publications, adding CNN, FT, Axios, Forbes — thione · 2026-10-26
- Anthropic: junior tech hires fell from 27% to 9% as agent hours hit 6x employee hours — thione · 2026-10-26